Patients previously untreated or treated with drug therapy for epithelioid hemangioendothelioma (EHE) are eligible; there is no limit on the number of prior regimens used to be eligible
Any number of prior recurrences are allowed
Progression of tumor or intolerance to therapies known to provide clinical benefit. There is no limit to the number of prior treatment regimens
Any number of prior treatment regimens
Any number of prior chemotherapy regimens are allowed
Since selumetinib is not expected to cause substantial myelosuppression, there will be no limit to number of prior myelosuppressive regimens previously received for NF related; or other tumor manifestations
Patients must have received prior treatment with a platinum containing regimen and may have received an unlimited number of prior regimens (including prior taxanes)
There is no limit on the number of prior treatment regimens
Prior therapy with abiraterone, enzalutamide and/or docetaxel; there is no limit to the number of prior treatment regimens
There is no limit to the number of prior treatment regimens provided that performance status and life expectancy meet the criteria above
There is no limit to the number of prior systemic treatment regimens
Phase I: patients are eligible with any number of prior regimens regardless of what those regimens contained (i.e. prior bortezomib or combination gemcitabine and adriamycin is acceptable)
There is no limit on number of prior regimens
Patients with any number of recurrences are allowed
Prior therapy with sipuleucel-T, abiraterone, enzalutamide, docetaxel, and/or cabazitaxel; there is no limit to the number of prior treatment regimens, so long as prior therapy does not include platinum chemotherapy or a PARP inhibitor
Part  patients may have an unlimited number of prior therapy regimens
Subjects who have platinum-resistant disease; there is no limit on the number of prior treatment regimens
Systemic chemotherapy washout period >=  days; for investigational dugs and monoclonal antibodies washout period >=  x drug half-life; there are no limitations on number of prior treatment regimens
Patients may have had prior systemic therapy without constraint on the number of prior treatment regimens except:\r\n* Patients may not have had >  mg/m^ doxorubicin \r\n* Patients may not have had >  centigray (cGy) to fields encompassing the entire pelvis
Must have failed at least  regimen for metastatic disease, and have been treated with up to  prior chemotherapy regimens\r\n* There is no limit on the number of total prior regimens
Disease progression after  prior ALK inhibitor therapy other than crizotinib. Patients may have had any number of prior chemotherapy regimens in any disease setting.
Disease progression after  prior ALK inhibitor therapies. Patients may have had any number of prior chemotherapy regimens in any disease setting.
Disease progression after  prior ALK inhibitor therapies. Patients may have had any number of prior chemotherapy regimens in any disease setting. ROS-positive NSCLC patients may be:
Patients are allowed to receive any number of prior chemotherapy regimens for recurrent disease
Group B any number of prior regimens.
Patients who have relapsed or are refractory to at least one prior chemotherapy regimen, and for whom no standard therapy exists; there is no limit to the number of prior chemotherapy regimens received
Any number of prior treatment regimens is allowed
Any number of prior chemotherapy regimens is allowed
There is no limit on the number of prior chemotherapy regimens allowed; any prior treatment (with the exception of lanreotide or octreotide) must be completed at least  weeks prior to initiation of treatment
Any number of prior regimens is allowed; prior investigational therapy is allowed
Receipt of no more than three prior chemotherapy regimens; monoclonal antibody therapy alone and involved field radiotherapy are not included in this number; prior use of ofatumumab is allowed if there has been no disease progression following that therapy (i.e. ofatumumab-based salvage regimens are allowed)
Any number of previous chemotherapy regimens (except those containing TMZ or dacarbazine [DTIC]) in the metastatic setting are allowed as long as >=  weeks have elapsed from last treatment
Any number of prior chemotherapy regimens is permitted
There is no limit on the number of prior treatment regimens
Patients must have had at least one prior therapy to be eligible for either the first or second stage a) Patients are eligible with any number of prior regimens regardless of what those regimens contained (i.e. prior Bortezomib or combination gemcitabine and adriamycin is acceptable).
PANCREATIC CANCER COHORT (COHORT  ONLY): Patients must have had at least one prior chemotherapy for advanced disease; there is no limit to the number of prior chemotherapy regimens received
Patients may have had any number of prior surgeries, radiation and/or chemotherapy regimens as adjuvant, neoadjuvant or palliative therapy for the treatment of their disease
Patients may have had treatment for an unlimited number of prior relapses
Any number of prior systemic therapeutic regimens including chemotherapy, pathway inhibitors, biochemotherapy, investigational agents, and immunotherapies other than ipilimumab or bavituximab
Patients must have progressed on or been intolerant to a fluoropyrimidine-based chemotherapy regimen; there is no limit on the number of prior treatment regimens permitted
Any number of prior treatment regimens are allowed
Patients may have an unlimited number of prior therapy regimens
Any number of prior regimens for recurrent or metastatic SCCHN (i.e. palliative treatment) but without cetuximab or another EGFR inhibitor
Any number of prior treatment regimens, including treatment naive subjects. Prior treatment with tyrosine kinase inhibitors is permitted.